JPH0218066B2 - - Google Patents
Info
- Publication number
- JPH0218066B2 JPH0218066B2 JP58050533A JP5053383A JPH0218066B2 JP H0218066 B2 JPH0218066 B2 JP H0218066B2 JP 58050533 A JP58050533 A JP 58050533A JP 5053383 A JP5053383 A JP 5053383A JP H0218066 B2 JPH0218066 B2 JP H0218066B2
- Authority
- JP
- Japan
- Prior art keywords
- urokinase
- molecular weight
- hsa
- modified
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005356 urokinase Drugs 0.000 claims description 28
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 26
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 26
- 239000007857 degradation product Substances 0.000 claims description 7
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 5
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 5
- 239000003431 cross linking reagent Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002715 modification method Methods 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- NQUNIMFHIWQQGJ-UHFFFAOYSA-N 2-nitro-5-thiocyanatobenzoic acid Chemical compound OC(=O)C1=CC(SC#N)=CC=C1[N+]([O-])=O NQUNIMFHIWQQGJ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- -1 bisimidates Substances 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58050533A JPS59175883A (ja) | 1983-03-28 | 1983-03-28 | アルブミン分解物を用いた修飾ウロキナ−ゼ及びその製造法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58050533A JPS59175883A (ja) | 1983-03-28 | 1983-03-28 | アルブミン分解物を用いた修飾ウロキナ−ゼ及びその製造法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59175883A JPS59175883A (ja) | 1984-10-04 |
| JPH0218066B2 true JPH0218066B2 (pl) | 1990-04-24 |
Family
ID=12861632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58050533A Granted JPS59175883A (ja) | 1983-03-28 | 1983-03-28 | アルブミン分解物を用いた修飾ウロキナ−ゼ及びその製造法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59175883A (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2572932Y2 (ja) * | 1991-05-13 | 1998-05-25 | 株式会社アドバンテスト | 高周波測定プローブ |
-
1983
- 1983-03-28 JP JP58050533A patent/JPS59175883A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59175883A (ja) | 1984-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2721830B2 (ja) | 改良された体組織結合特異性を有する薬剤活性抱合体 | |
| Steffen et al. | Immunogenicity and specificity of collagen: V. Demonstration of three different antigenic determinants on calf collagen | |
| JPH02223599A (ja) | 合成抗原およびその製造方法 | |
| JPH11509721A (ja) | 高純度フォンビルブラント因子の入手方法 | |
| US4056520A (en) | Clinically active bovine growth hormone fraction | |
| JPH0736760B2 (ja) | プロテインｃの定量測定法及び活性化剤調製物 | |
| JPH0443638B2 (pl) | ||
| NZ582669A (en) | Hydrolysable polymeric FMOC-linker | |
| JPH08502498A (ja) | 低アレルゲン性タンパク質 | |
| JP2001513762A (ja) | 高度に精製されたｖＷＦまたは因子ＶＩＩＩ／ｖＷＦ複合体を得る方法 | |
| MXPA03000566A (es) | Complejo de proteina que sirve como vehiculo para faramcos que pueden administrarse por via oral. | |
| JP2735233B2 (ja) | 合成ペプチドおよびそれに対する抗体 | |
| Huang et al. | Investigation of the allergenicity of β-lactoglobulin and its cleavage fragments | |
| WO1991008220A1 (en) | A method for the stepwise, controlled synthesis of chemical species, particularly peptides, coupled products obtained by the method and the use of these coupled products, e.g. as vaccines | |
| EP0152612B1 (de) | Bestimmung von Fibrin mit Fibrin-spezifischen Antikörpern | |
| US4029765A (en) | Derivatives of the tetanus toxin, process for their preparation and agents containing them | |
| US4177262A (en) | Plasminogen compositions containing preactivated plasminogens with or without native plasminogens, process for making same, pharmaceutical compositions and control of blood clots | |
| JPH0218066B2 (pl) | ||
| EP0359428B1 (en) | Protein derivatives and a process for their preparation | |
| US4033819A (en) | Derivatives of diphtheria toxin, process for preparing them and agents containing them | |
| JPS63123395A (ja) | 抗ｐｃｉモノクローナル抗体、これを用いた抗ｐｃｉの精製法及び免疫学的測定法 | |
| US3904753A (en) | Clinically active bovine growth hormone fraction | |
| JPH05340948A (ja) | 鶏卵抗体固定化担体およびその固定化方法 | |
| JPH06505496A (ja) | 活性因子ｘ１１１の活性化を阻害するための組成物と方法 | |
| Suyama et al. | Enzymatic evidence for differences in the placement of Rh antigens within the red cell membrane |